Browse by author
Lookup NU author(s): David Mott
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The question of whose preferences to elicit in health-state valuation has been widely discussed in the literature. The importance of this debate lies in the fact that health-state utility values are used in health technology assessment (HTA); therefore, an individual's preferences can influence decision-making. If preferences differ across groups, making decisions based on one group's preferences may be suboptimal for the other. Preferences for benefits, risks, experiences and health states associated with anticoagulant therapies have been elicited by researchers due to the underutilization of warfarin and the introduction of non-vitamin K antagonist oral anticoagulants. The majority of existing studies elicit preferences from patient populations as opposed to other stakeholders such as the general public. This paper extends the preference debate by using this clinical area as a case study, with a particular focus on HTA guidelines and the recent advocacy of the use of preference information in benefit-risk assessments.
Author(s): Mott DJ, Najafzadeh M
Publication type: Article
Publication status: Published
Journal: Expert Review of Pharmacoeconomics & Outcomes Research
Print publication date: 01/01/2016
Online publication date: 20/11/2015
Acceptance date: 11/11/2015
ISSN (print): 1473-7167
ISSN (electronic): 1744-8379
Publisher: Taylor & Francis Inc.
Altmetrics provided by Altmetric